fda reconsiders tirzepatide US to reconsider decision barring compounded versions of Lilly weight loss drug UPDATE [March 7, 2025]: OFA
Pay in 4 interest-free payments of $5.53 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
![fda reconsiders tirzepatide US to reconsider decision barring compounded versions of Lilly weight loss drug UPDATE [March 7, 2025]: OFA](https://static.wixstatic.com/media/60489a_95b142b425f4416b99f8a052fde88da7~mv2.jpg/v1/fill/w_980,h_551,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/60489a_95b142b425f4416b99f8a052fde88da7~mv2.jpg)
![fda reconsiders tirzepatide US to reconsider decision barring compounded versions of Lilly weight loss drug UPDATE [March 7, 2025]: OFA](https://www.pharmacypracticenews.com/aimages/2024/Tirzepatide_Lead.jpg)
![fda reconsiders tirzepatide US to reconsider decision barring compounded versions of Lilly weight loss drug UPDATE [March 7, 2025]: OFA](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/12/GettyImages-2092473215-430x241.jpg)





















